SCHEDULE 13D: Pyu Pyu Capital Invests $3M in BiomX, Gains Board Seat

Pyu Pyu Capital, LLC has acquired a 19.99% beneficial ownership stake in BiomX Inc. through a $3.0 million private placement of convertible preferred stock and warrants, securing a board seat.

Summary

• Pyu Pyu Capital, LLC and its managing member, Reuven Yeganeh, reported a 19.99% beneficial ownership in BiomX Inc.
• This ownership stems from a private placement where BiomX Inc. issued 3,300 shares of Series Y Convertible Preferred Stock and warrants to purchase 3,300,000 shares of Common Stock.
• The transaction generated aggregate gross proceeds of $3.0 million for BiomX Inc.
• The Series Y Preferred Stock has a stated value of $1,000 per share, a 15% annual dividend (cash or stock), and a one-year maturity.
• Both the preferred stock and warrants have an initial conversion/exercise price of $2.00 per share, subject to adjustment and a potential reduction post-stockholder approval.
• Pyu Pyu Capital's beneficial ownership is capped at 19.99% prior to stockholder approval for conversions/exercises.
• Reuven Yeganeh, Managing Member of Pyu Pyu Capital, was appointed to BiomX Inc.'s Board of Directors as a Class 1 director, effective upon closing.
• BiomX Inc. is required to hold a stockholders' meeting within 60 days of closing to approve the issuance of shares exceeding 19.99% of outstanding common stock, as per NYSE American rules.
• BiomX Inc. also entered into a Registration Rights Agreement, obligating it to file a resale registration statement for the underlying common shares within 30 days of closing.

Sentiment

Score: 7

Explanation: The filing indicates a successful capital raise for BiomX Inc., providing $3.0 million in gross proceeds and securing a strategic investor with board representation. While the 15% preferred dividend is high and future dilution is a factor, the immediate capital infusion and investor confidence are positive. The need for stockholder approval for full conversion/exercise introduces a minor contingency.

Positives

• BiomX Inc. secured $3.0 million in gross proceeds, strengthening its financial position.
• The investment from Pyu Pyu Capital provides a new strategic investor with board representation.
• The Series Y Preferred Stock offers a 15% annual dividend, providing income to Pyu Pyu Capital.
• The warrants provide Pyu Pyu Capital with potential upside exposure to BiomX Inc.'s common stock.

Negatives

• The 15% annual dividend on Series Y Preferred Stock represents a significant ongoing cost for BiomX Inc.
• The potential reduction in conversion/exercise price post-stockholder approval could lead to greater dilution for existing shareholders.
• The requirement for stockholder approval for full conversion/exercise beyond 19.99% introduces a contingency.
• The issuance of preferred stock and warrants will lead to dilution for existing common stockholders upon conversion/exercise.

Risks

• Dilution Risk: Future conversion of Series Y Preferred Stock and exercise of Warrants will dilute the ownership of existing common stockholders.
• Stockholder Approval Risk: The issuance of shares exceeding 19.99% of outstanding common stock requires stockholder approval, which is not guaranteed. Failure to obtain approval could impact Pyu Pyu Capital's ability to fully convert/exercise.
• Conversion/Exercise Price Volatility: The conversion and exercise prices are subject to adjustment and potential reduction based on the common stock's market price, which could lead to more shares being issued.
• Preferred Stock Seniority: The Series Y Preferred Stock ranks senior to Common Stock and Series X Non-Voting Convertible Preferred Stock regarding dividends, distributions, and liquidation, potentially impacting common stockholders in adverse scenarios.
• Market Risk: The value of the Warrants and the underlying Common Stock is subject to market fluctuations.

Future Outlook

BiomX Inc. is obligated to hold a stockholders' meeting within 60 calendar days of the closing to seek approval for the issuance of common stock exceeding 19.99% of its outstanding shares, which is necessary for Pyu Pyu Capital to fully convert its preferred stock and exercise its warrants without beneficial ownership limitations. The company also committed to filing a resale registration statement for the underlying common shares within 30 days of closing and to use commercially reasonable efforts to have it declared effective within 60-90 days.

Industry Context

This private placement provides a capital infusion for BiomX Inc., a biotechnology company, which is common for firms in this sector that often require significant funding for research, development, and operational expenses. The inclusion of convertible preferred stock and warrants, along with board representation for the investor, suggests a strategic partnership aimed at supporting the company's long-term growth, while also providing the investor with significant influence and potential upside.

Management Changes

Corporate Governance

Related Party Transactions

• The Securities Purchase Agreement, Certificate of Designations, Form of Warrant, and Registration Rights Agreement were entered into between BiomX Inc. and Pyu Pyu Capital, LLC, which is now a significant beneficial owner and has a designated director on the board, making these related party dealings.

Stakeholder Impact

• Shareholders: Existing common shareholders face potential dilution from the conversion of preferred stock and exercise of warrants. However, the capital raise provides funding for the company's operations. The 15% dividend on preferred stock is a cost that could impact future earnings available to common shareholders.
• Company (BiomX Inc.): Receives $3.0 million in gross proceeds, strengthening its balance sheet and providing capital for operations. Gains a strategic investor and board member.
• Pyu Pyu Capital, LLC: Becomes a significant beneficial owner (19.99%) with board representation, gaining influence and potential returns from the preferred stock dividends and warrant exercise.

Next Steps

• BiomX Inc. must hold a stockholders' meeting within 60 calendar days of January 13, 2026, to approve the issuance of common stock exceeding 19.99% of outstanding shares.
• BiomX Inc. must file a resale registration statement with the SEC within 30 calendar days of January 13, 2026.
• BiomX Inc. must use commercially reasonable efforts to cause the registration statement to be declared effective by the SEC within 60 calendar days (or 90 days if reviewed) of January 13, 2026.
• BiomX Inc. must maintain the effectiveness of the registration statement for the period specified in the Registration Rights Agreement.
• Pyu Pyu Capital will continue to review its investment and may acquire or dispose of additional securities.

Key Dates

Recommendation

The capital raise provides necessary funding for BiomX Inc., which is a positive for its operational runway. However, the significant dilution potential from the convertible preferred stock and warrants, coupled with a high 15% dividend rate on the preferred shares, introduces considerable future obligations and potential downward pressure on common stock value. The need for stockholder approval for full conversion/exercise also adds a layer of uncertainty. While the investment provides stability, the terms suggest a cautious approach for existing common shareholders until the full impact of dilution and the company's strategic direction with the new capital become clearer.

Keywords

BiomX Inc., Pyu Pyu Capital, Schedule 13D, Private Placement, Convertible Preferred Stock, Warrants, Equity Investment, Board Appointment, Shareholder Activism, Biotechnology, SEC Filing, Dilution, Corporate Governance